ClinicalTrials.gg
Not yet recruitingNCT07943052Updated Nov 17, 2026

Intrauterine Misoprostol in Cesarean Delivery: Effect on Postpartum Hemorrhage

A Phase 4 interventional study of Misoprostol and Oxytocin in Postpartum Hemorrhage and Cesarean Section, sponsored by Bagcilar Training and Research Hospital. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Bagcilar Training and Research Hospital · Phase 4, Interventional, and Prevention

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Postpartum Hemorrhage with a site in Turkey — 4 open to participants now, 5 under way, none of them phase 3. Postpartum Hemorrhage · Turkey.

Planned enrollment
19th of 34
142 · median 148
Started
2026
with 2 others
Phase 4
4 of 44
1 open now
Registered
44th of 44
by date
Lead sponsor
2 of 44
Bagcilar Training and Research Hospital

Among the 44 studies in Postpartum Hemorrhage with a site in Turkey, this one is the 19th largest by planned enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2026, is one of 4 in phase 4, and was the 44th registered.

Postpartum Hemorrhage

470 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.

Browse Postpartum Hemorrhage studies →

Open to participants now

4 of the 44 studies in Postpartum Hemorrhage with a site in Turkey are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Postpartum Hemorrhage with a site in Turkey, or all of them as a file.
02

Study summary

This prospective, randomized, controlled, two-arm study evaluates whether adding intrauterine (uterine cornual) misoprostol 400 mcg to standard oxytocin reduces postpartum blood loss in term women undergoing elective cesarean delivery. Participants are randomized 1:1 to standard oxytocin alone or standard oxytocin plus misoprostol. The primary outcome is the change in hemoglobin and hematocrit from preoperative values to 6, 24 and 48 hours after surgery.

Read the detailed description

A total of 142 women (71 per group) will be enrolled. The study group receives standard oxytocin plus a single 400 mcg dose of misoprostol placed in the uterine cornual region after placental delivery; the control group receives standard oxytocin only. Hemoglobin and hematocrit are measured before surgery and at 6, 24 and 48 hours afterwards, and participants are seen on postoperative day 10 for late complications and adverse events. The surgical team is not masked; participants are not informed of their allocation. An interim safety analysis is planned after 50 participants.

03

Conditions studied

  • Postpartum Hemorrhage
  • Cesarean Section

Browse trials for

Keywords

  • Intrauterine misoprostol
  • oxytocin
  • elective cesarean section
  • hemoglobin
  • hematocrit
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-45 years
  • Term pregnancy (37 weeks or more)
  • Elective cesarean section planned
  • Written signed

Exclusion criteria

Exclusion Criteria:

  • History of coagulopathy or active bleeding disorder
  • Anticoagulant use
  • \< 10 g/dL
  • Active thromboembolic disease
  • Severe hepatic failure
  • > 35 kg/m2
  • Type 1 diabetes with diabetic nephropathy
  • Chronic hypertension
  • Gestational hypertension, preeclampsia, eclampsia or HELLP syndrome
  • Placenta previa, placental abruption or placental pathology with high bleeding risk
  • Multiple pregnancy
  • Uterine anomalies
  • Intrauterine fetal death
  • Epilepsy (diagnosis or history)
  • Active
  • Known to prostaglandins
  • Refusal or withdrawal of consent
  • Emergency-indicated cesarean sections (including those planned as elective but performed for fetal distress, uterine rupture or other emergency indications)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
142 participants (estimated)

Study arms

  • Experimental
    Misoprostol plus standard oxytocin

    Standard oxytocin plus a single 400 mcg dose of misoprostol placed in the uterine cornual region after delivery of the placenta during elective cesarean delivery.

    Drug: Misoprostol · Drug: Oxytocin

  • Active comparator
    Standard oxytocin

    Standard oxytocin only, according to routine clinical practice, during elective cesarean delivery.

    Drug: Oxytocin

Interventions

  • DrugMisoprostol

    Misoprostol 400 mcg (2 x 200 mcg tablets), single dose placed in the uterine cornual region after delivery of the placenta, in addition to standard oxytocin.

  • DrugOxytocin

    Standard oxytocin administered after delivery of the baby according to routine clinical practice (standard of care in both arms).

06

What researchers measure

Primary outcomes

  1. Change in hemoglobin from preoperative value to postoperative 6, 24 and 48 hours

    Hemoglobin (g/dL) measured before surgery and at 6, 24 and 48 hours after surgery; change from the preoperative value is compared between groups.

    Time frame: Preoperative, and 6, 24 and 48 hours after surgery

  2. Change in hematocrit from preoperative value to postoperative 6, 24 and 48 hours

    Hematocrit (%) measured before surgery and at 6, 24 and 48 hours after surgery; change from the preoperative value is compared between groups.

    Time frame: Preoperative, and 6, 24 and 48 hours after surgery

Secondary outcomes

  1. Need for blood transfusion

    Proportion of participants requiring blood transfusion after surgery.

    Time frame: From surgery until hospital discharge, up to 48 hours

  2. Need for additional uterotonic or hemostatic intervention

    Proportion of participants requiring additional uterotonic agents or other hemostatic interventions.

    Time frame: During surgery and until hospital discharge, up to 48 hours

  3. Late postoperative complications and readmission

    Late complications and hospital readmission assessed at the postoperative day 10 visit.

    Time frame: Up to postoperative day 10

  4. Misoprostol-related adverse events

    Adverse events potentially related to misoprostol (e.g., fever, shivering, nausea, vomiting, diarrhea) recorded in both groups.

    Time frame: Up to postoperative day 10

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jun 2027, 7 months later.

Of 27 non-industry phase 4 interventional studies under Postpartum Hemorrhage, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 20. This study's planned 7 months is below that.

Counting every sponsor, half of 28 studies reached it within 12 months; a quarter within 10 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Nov 23, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943052
Lead sponsor
Bagcilar Training and Research Hospital
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 23, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Halil Gümüş, MD
Contact
dr.halil.gumusrc@gmail.com
+90 537 673 47 49
Cem Yener, MD, Associate Professor
principal investigator · Bagcilar Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion